Pfizer Inc. (NYSE:PFE) Shares Sold by Flynn Zito Capital Management LLC

Flynn Zito Capital Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 24.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,541 shares of the biopharmaceutical company’s stock after selling 4,293 shares during the quarter. Flynn Zito Capital Management LLC’s holdings in Pfizer were worth $379,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Private Advisor Group LLC grew its holdings in Pfizer by 12.8% during the second quarter. Private Advisor Group LLC now owns 735,962 shares of the biopharmaceutical company’s stock worth $20,592,000 after acquiring an additional 83,754 shares during the period. New York Life Investment Management LLC boosted its position in Pfizer by 0.7% in the 2nd quarter. New York Life Investment Management LLC now owns 801,836 shares of the biopharmaceutical company’s stock worth $22,435,000 after purchasing an additional 5,603 shares in the last quarter. Addison Advisors LLC grew its stake in shares of Pfizer by 23.2% during the 2nd quarter. Addison Advisors LLC now owns 10,570 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 1,992 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of Pfizer by 5.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 50,904 shares of the biopharmaceutical company’s stock valued at $1,424,000 after purchasing an additional 2,749 shares in the last quarter. Finally, Farmers & Merchants Investments Inc. lifted its stake in shares of Pfizer by 2.5% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 208,076 shares of the biopharmaceutical company’s stock valued at $5,822,000 after purchasing an additional 5,087 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on PFE. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. UBS Group raised their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Up 0.2 %

Shares of PFE opened at $28.56 on Friday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.64. The stock has a market cap of $161.84 billion, a PE ratio of -476.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The firm’s fifty day moving average is $29.06 and its two-hundred day moving average is $28.05. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm posted $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.